Rare Disease and the Question After the Click

“Ask your doctor” takes three words in an ad. The conversation it sets in motion deserves rather more space in the media plan.

Picture the moment your message reaches the consulting room. A patient with a rare disease has saved a treatment name on their phone. They have taken your message seriously enough to bring it to their doctor. The question is personal: Could this help me?

The clinician needs to understand the evidence, explain who might be eligible and discuss what happens next. When patient awareness gets ahead of that preparation, a campaign can raise expectations the consultation cannot yet resolve.

Feedback from the BioNews patient council, shared with CMI Media Group, highlights this gap between patient awareness and healthcare professional (HCP) knowledge. For brand and media teams, it makes clinician preparation part of the launch decision. In rare disease, the real assignment is shortening a diagnostic odyssey that often spans years and multiple misdiagnoses—and that timeline will not shrink if an empowered patient brings a question to an unprepared room.

Our Media Vitals Consumer Rare Disease research adds context. Among 82 respondents in the rare disease subgroup, 17% reported feeling frustrated after a doctor visit, compared with 8% of the total survey sample. The study does not identify the cause, but it does give marketers a reason to think carefully about the experience that follows a call to action.

The questions start before the appointment

Your campaign may join a search for answers already well under way. In the same research, 52% of rare disease respondents reported using AI apps or sites for health information, compared with 38% overall.

That should earn a place in the creative brief. Alongside the messages you want patients to remember, identify what they may need their doctor to explain. A clinician might have to put an AI response into context or explain why a treatment discussed online is not necessarily appropriate for the person in front of them.

This dynamic makes Generative Engine Optimization (GEO) an essential pre-launch discipline alongside traditional search—ensuring AI models synthesize authoritative, medically sound ground truth so the information reaching the consultation clarifies rather than misleads. 

The brief becomes more useful when it anticipates that conversation. HCP education can address the questions patient content is likely to generate, with evidence that is easy to find and revisit.

These findings are directional: The group is small and spans several conditions. Use them to sharpen research within your disease community, including where patients find information and where uncertainty remains.

The clinicians your target list could miss

The clinician who writes the prescription may be several conversations away from the patient’s first question. Someone first has to recognize a possible condition, consider the next step and make the referral. Those roles deserve attention in the media brief.

Getting to care can be a challenge in itself. In our rare disease subgroup, 38% reported putting off or cancelling an appointment in the previous 12 months because the distance was too far, compared with 25% overall. For a patient facing that barrier, a useful next step needs practical detail, including any available travel support or remote consultation options. From a media perspective, that distance also opens up an opportunity: Streaming audio can reach patients and caregivers during the long drive to care, offering thoughtful context when they are focused entirely on the road ahead.

Ask agency and publishing partners to show how their recommendations serve each clinical role. A referring clinician may need disease awareness content and referral guidance. A treating specialist may need detailed eligibility information and evidence on benefits, risks and quality of life. The audience strategy should explain those differences before the channel plan tries to reach them.

CMI Media Group’s Rare Disease Center of Excellence combines specialist strategy, audience research and data to map care pathways and distinguish prescribers from referrers. That understanding gives brand teams a clearer basis for audience selection and media investment.

Give the answer a head start

Put the HCP and patient plans on the table together, while there is still time to change them. Work through the consultation your campaign could prompt. If patient content introduces a treatment possibility, professional resources should explain its relevance, the evidence behind it and any further assessment required.

Then, follow the question one step further. Interest in a treatment soon raises practical questions about access. In our rare disease subgroup, 34% rated awareness of a copay program as very influential in decisions about changing medication, compared with 24% overall. This measures reported influence, rather than actual switching, and makes support information a clear consideration for the content plan.

Resources will differ by market. Make the relevant access information easy to find and any conditions attached easy to understand. Apply the same care to quality-of-life claims, so both audiences have expectations grounded in the evidence and its limitations.

Agree on timing and investment with brand, media and medical colleagues before the launch calendar is fixed. Give HCPs time to engage with the education before turning up patient-facing activity. Whether the campaign concerns disease awareness or, where permitted, a specific treatment, keep those plans connected as new questions emerge.

The conversation is the real test

Keep reach and engagement on the dashboard, then ask what the educational content helped its audience understand.

In our research, 20% of rare disease respondents named patient support groups as their most helpful source of health information, compared with 13% overall. Bring those community perspectives into content evaluation. The questions shared within patient networks reveal what a campaign explains well and what it leaves unanswered, guiding the development of practical tools—like discussion guides and symptom checklists—that patients carry into the visit.

For HCPs, research before and after activity can assess understanding of eligibility or confidence in discussing the evidence. Repeat use of referral guidance and feedback on unanswered questions can inform the next round of content and investment. These are signals for improving communications, rather than proof that media alone has changed clinical outcomes.

Return to the patient with the treatment name on their phone. A useful consultation might lead to further assessment, a referral or an explanation of why that treatment is unsuitable. The aim is clarity about what the information means for them and what they can do next.

The click may start the conversation. Your launch plan should help prepare the person who answers.

Research source: CMI Media Group, Media Vitals™ Consumer Rare Disease Summary; rare disease subgroup n=82 across multiple conditions. All comparisons are with the total survey sample.